Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter
Launched by BEIJING DITAN HOSPITAL · Feb 10, 2020
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meet the criteria of hepatocellular carcinoma
- • Ages Eligible for Study: ≤75 years old;
- • The size of the main nodule and multi-centricity (single lesion, three nodules ≤3 cm)
- • After transarterial chemoembolisation (TACE) or radiofrequency ablation (RFA)
- • Surgery cannot be allowed;
- • Informed consent from the patient.
- Exclusion Criteria:
- • Serious problem of heart, lung, or kidney with severe dysfunction;
- • Pregnant or child breast feeding women;
- • Mental or cognitive disorders;
- • Participating in other drug trials;
- • Who are allergic to the study drug.
About Beijing Ditan Hospital
Beijing Ditan Hospital is a leading healthcare institution in China, renowned for its expertise in neurology and neurosurgery. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a commitment to ethical standards and patient safety, Beijing Ditan Hospital collaborates with multidisciplinary teams to explore new therapies and interventions, contributing to the global body of knowledge in the medical field. Its state-of-the-art facilities and experienced researchers position the hospital at the forefront of clinical research, fostering breakthroughs that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials